New hope for Tough-to-Treat ovarian cancers in early trial

NCT ID NCT04092270

Ongoing Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

Summary

This early-stage study is testing a new two-drug combination for women with ovarian cancer that has returned after previous treatment. The main goal is to find the safest and most effective dose of an experimental pill (peposertib) when given with a standard chemotherapy drug. Researchers will monitor patients closely for side effects and see if the combination helps control the cancer better than the chemotherapy alone.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE HIGH GRADE SEROUS ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Emory University Hospital/Winship Cancer Institute

Atlanta, Georgia, 30322, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Memorial Sloan Kettering Monmouth

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Westchester

Harrison, New York, 10604, United States
Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43210, United States
UCHealth University of Colorado Hospital

Aurora, Colorado, 80045, United States
University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, 73104, United States
University of Pittsburgh Cancer Institute (UPCI)

Pittsburgh, Pennsylvania, 15232, United States
University of Virginia Cancer Center

Charlottesville, Virginia, 22908, United States
University of Wisconsin Carbone Cancer Center - University Hospital

Madison, Wisconsin, 53792, United States

Conditions

Explore the condition pages connected to this study.

ENDOMETRIAL HIGH GRADE ENDOMETRIOID ADENOCARCINOMA FALLOPIAN TUBE CARCINOSARCOMA FALLOPIAN TUBE CLEAR CELL ADENOCARCINOMA FALLOPIAN TUBE ENDOMETRIOID ADENOCARCINOMA FALLOPIAN TUBE HIGH GRADE SEROUS ADENOCARCINOMA FALLOPIAN TUBE MALIGNANT MIXED MESODERMAL (MULLERIAN) TUMOR FALLOPIAN TUBE MUCINOUS ADENOCARCINOMA FALLOPIAN TUBE TRANSITIONAL CELL CARCINOMA FALLOPIAN TUBE UNDIFFERENTIATED CARCINOMA FIGO GRADE 1 ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA FIGO GRADE 2 ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA OVARIAN HIGH GRADE SEROUS ADENOCARCINOMA OVARIAN SEROMUCINOUS CARCINOMA OVARIAN UNDIFFERENTIATED CARCINOMA PLATINUM-SENSITIVE OVARIAN CARCINOMA PRIMARY PERITONEAL CARCINOSARCOMA PRIMARY PERITONEAL HIGH GRADE SEROUS ADENOCARCINOMA PRIMARY PERITONEAL TRANSITIONAL CELL CARCINOMA PRIMARY PERITONEAL UNDIFFERENTIATED CARCINOMA RECURRENT FALLOPIAN TUBE CARCINOMA RECURRENT LOW GRADE FALLOPIAN TUBE SEROUS ADENOCARCINOMA RECURRENT OVARIAN CARCINOMA RECURRENT OVARIAN CARCINOSARCOMA RECURRENT OVARIAN CLEAR CELL ADENOCARCINOMA RECURRENT OVARIAN ENDOMETRIOID ADENOCARCINOMA RECURRENT OVARIAN LOW GRADE SEROUS ADENOCARCINOMA RECURRENT OVARIAN MALIGNANT MIXED MESODERMAL (MULLERIAN) TUMOR RECURRENT OVARIAN MUCINOUS ADENOCARCINOMA RECURRENT OVARIAN TRANSITIONAL CELL CARCINOMA RECURRENT PRIMARY PERITONEAL CARCINOMA RECURRENT PRIMARY PERITONEAL LOW GRADE SEROUS ADENOCARCINOMA